Bayer’s Contested Kidney Cancer Drug Shows Benefit

Final results from a mid-stage clinical trial involving a sister compound to Bayer AG’s Nexavar have confirmed the drug’s potential, raising the stakes in a legal tussle with development partner Onyx Pharmaceuticals Inc.
CNBC